ホーム>>Signaling Pathways>> Cell Cycle/Checkpoint>> c-Myc>>10074-A4

10074-A4

カタログ番号GC63576

10074-A4 は c-Myc 阻害剤です。 10074-A4 は、ペプチド鎖に沿った異なる部位で c-Myc370-409 に結合できます。 10074-A4 には抗がん効果があります。

Products are for research use only. Not for human use. We do not sell to patients.

10074-A4 化学構造

Cas No.: 312631-87-1

サイズ 価格 在庫数 個数
5 mg
$252.00
在庫あり
10 mg
$378.00
在庫あり
25 mg
$576.00
在庫あり
50 mg
$864.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

10074-A4 is a c-Myc inhibitor. 10074-A4 could bind to c-Myc370-409 at different sites along the peptide chain. 10074-A4 has anticancer effects[1][2].

10074-A4 shows inhibitory activity of HL-60 cells with an IC50 of 15.1 μM[1].10074-A4 (25-50 μM; 24 hours) arrests the cell cycle at the S-phase in a dose-dependent manner in HL-60 cells. 10074-A4 inhibits the mRNA level of the c-Myc target genes, CCND2 and CDK4[1].10074-A4 could bind to c-Myc370-409 at different sites along the peptide chain and its binding behavior could be described as a ’ligand cloud’. Even in the bound state, the structure of the c-Myc370-409 peptide remained a dynamic ensemble. The 10074-A4 ligand bound at different sites throughout the c-Myc370-409 chain with different strength[2].

[1]. Chen Yu, et al. Structure-based Inhibitor Design for the Intrinsically Disordered Protein c-Myc. Sci Rep. 2016 Mar 2;6:22298.
[2]. Fan Jin, et al. Ligand clouds around protein clouds: a scenario of ligand binding with intrinsically disordered proteins. PLoS Comput Biol. 2013;9(10):e1003249.

レビュー

Review for 10074-A4

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 10074-A4

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.